BofA Securities Reiterates Neutral Rating on Cytokinetics (CYTK)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Goldman Sachs Reiterates Neutral Rating on Cytokinetics (CYTK)
September 9, 2024 12:11 PM EDTGoldman Sachs analyst Paul Choi reiterated a Neutral rating and $60.00 price target on Cytokinetics (NASDAQ: CYTK).
The analyst comments "Overall consistent results support advancing CK-586 into Phase 2 studies though greater conviction remains elusive for now. We reviewed the results of a Phase 1... More
Here's the list of biotech stocks that have key data catalysts in 2025
September 7, 2024 8:00 PM EDTWith only around 4 months left for 2024 to end, Piper Sandler analysts have identified 22 biotechnology stocks with key data catalysts/ approvals in 2025.
We looked at our coverage to look for data and approval driven catalysts that provide buying opportunities as the year is coming to a close, the firm told its clients in a note.
Among stocks with a market cap of over $1 billion, the firm identified 10 names.
1. Cytokinetics Inc. (NASDAQ: CYTK): With rolling submission expected to finish in 3Q24, we calculate potential aficamten oHCM... More
